NCT03714737View on ClinicalTrials.gov

Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese

PHASE3CompletedINTERVENTIONAL

Enrollment

1,950

Participants

Timeline

Start Date

May 12, 2016

Primary Completion Date

September 11, 2017

Study Completion Date

September 6, 2018

Conditions

Vaccine

Interventions

BIOLOGICAL

experimental vaccine

bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

BIOLOGICAL

Positive control vaccine 1

bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)

BIOLOGICAL

Positive control vaccine 2

bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)

All Listed Sponsors

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT03714737 - Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese | Biotech Hunter | Biotech Hunter